Inventor · disambiguated record
Per Norlen
Also filed as: NORLEN PER · NORLÉN PER
6 granted patents·6 pending applications·2 citations·filing 2014–2021
70Inventor score
Files withALLIGATOR BIOSCIENCE AB12
Top patents by PatentIndex Score
12 records- 0180US11008396B2PolypeptidesALLIGATOR BIOSCIENCE AB·Filed 2016·Granted May 18, 2021·2 cites·10 claims
- 0272US11780928B2PolypeptidesALLIGATOR BIOSCIENCE AB·Filed 2021·Granted Oct 10, 2023·0 cites·15 claims
- 0366US12173082B2Bispecific polypeptides against CD137ALLIGATOR BIOSCIENCE AB·Filed 2021·Granted Dec 24, 2024·0 cites·17 claims
- 0466US2021403589A1Combination therapies with anti cd40 antibodiesALLIGATOR BIOSCIENCE AB·Filed 2021·Application pending·0 cites
- 0565US10774150B2PolypeptidesALLIGATOR BIOSCIENCE AB·Filed 2020·Granted Sep 15, 2020·0 cites·12 claims
- 0657US12415862B2Methods and compositionsALLIGATOR BIOSCIENCE AB·Filed 2021·Granted Sep 16, 2025·0 cites·20 claims
- 0754US11149090B2Combination therapies with anti CD40 antibodiesALLIGATOR BIOSCIENCE AB·Filed 2015·Granted Oct 19, 2021·0 cites·16 claims
- 0843US2019169308A1Novel bispecific polypeptides against cd137ALLIGATOR BIOSCIENCE AB·Filed 2017·Application pending·0 cites
- 0943US2017304437A1Bispecific molecules capable of specifically binding to both ctla-4 and cd40ALLIGATOR BIOSCIENCE AB·Filed 2014·Application pending·0 cites
- 1042US2020048358A1Bispecific antibody against ox40 and ctla-4ALLIGATOR BIOSCIENCE AB·Filed 2018·Application pending·0 cites
- 1138US2019161555A1Bispecific Antibodies Directed Against OX40 and a Tumor-Associated AntigenALLIGATOR BIOSCIENCE AB·Filed 2017·Application pending·0 cites
- 1237US2019309084A1Bispecific Polypeptides to GITR and CTLA-4ALLIGATOR BIOSCIENCE AB·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Per Norlen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →